Hikma Pharmaceutical - Total Voting Rights

Hikma Pharmaceuticals PLC (Other OTC: HKMPF.PK - news) - Voting Rights and Capital

LONDON, 2 April 2012 Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) notifies the market that as at 31 March 2012 its capital consists of 196,806,607 ordinary shares with voting rights. There are no shares held in treasury.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Hikma Pharmaceuticals PLC under the FSA's Disclosure and Transparency Rules.

- ENDS -

Enquiries:

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non‐branded generic and in‐licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe (Chicago Options: ^REURUSD - news) . In 2011, Hikma achieved revenue of $918.0 million and profit attributable to shareholders of $80.1 million.